Ceftriaxone contraindications: Difference between revisions

Jump to navigation Jump to search
(Created page with "_NOTOC__ {{Ceftriaxone}} {{CMG}};{{AE}}{{AK}} Ceftriaxone for injection is contraindicated in patients with known allergy to the cephalosporin class of antibiotics. '''Neonat...")
 
No edit summary
 
Line 1: Line 1:
_NOTOC__
__NOTOC__
{{Ceftriaxone}}
{{Ceftriaxone}}
{{CMG}};{{AE}}{{AK}}
{{CMG}};{{AE}}{{AK}}
Ceftriaxone for injection is contraindicated in patients with known allergy to the cephalosporin class of antibiotics.
Ceftriaxone for injection is contraindicated in patients with known allergy to the cephalosporin class of antibiotics.



Latest revision as of 17:36, 31 December 2013

Ceftriaxone
CEFTRIAXONE®,ROCEPHIN® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
Clinical Studies
Compatibility and Stability
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]

Ceftriaxone for injection is contraindicated in patients with known allergy to the cephalosporin class of antibiotics.

Neonates (≤28 days)

Hyperbilirubinemic neonates, especially prematures, should not be treated with ceftriaxone for injection. In vitro studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin, leading to a possible risk of bilirubin encephalopathy in these patients.

Ceftriaxone for injection is contraindicated in neonates if they require (or are expected to require) treatment with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition because of the risk of precipitation of ceftriaxone-calcium (see CLINICAL PHARMACOLOGY, WARNINGS and DOSAGE AND ADMINISTRATION).

A small number of cases of fatal outcomes in which a crystalline material was observed in the lungs and kidneys at autopsy have been reported in neonates receiving ceftriaxone for injection and calcium-containing fluids. In some of these cases, the same intravenous infusion line was used for both ceftriaxone for injection and calcium-containing fluids and in some a precipitate was observed in the intravenous infusion line. At least one fatality has been reported in a neonate in whom ceftriaxone for injection and calcium-containing fluids were administered at different time points via different intravenous lines; no crystalline material was observed at autopsy in this neonate. There have been no similar reports in patients other than neonates.


References

http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/050796lbl.pdf